EUVIMEDEUVIMED entdecken
Crossref

Association between Early Guanfacine Discontinuation and Somnolence for Attention-Deficit/Hyperactivity Disorder

Kinuka Doi, Rintaro Sogawa, Yuko Eguchi, Muneaki Matsuo, Chisato Shimanoe

Biological and Pharmaceutical Bulletin · 2024

DOI: 10.1248/bpb.b24-00147 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Biological and Pharmaceutical Bulletin, 2024. Verfasst von Kinuka Doi und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Saga University Hospital. Hauptthemen laut MEDLINE: Guanfacine, Attention Deficit Disorder with Hyperactivity. Die Arbeit nennt 21 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Guanfacine, used as a medication for attention-deficit/hyperactivity disorder (ADHD), leads to a high incidence of somnolence, in contrast to methylphenidate, which leads to a high incidence of insomnia. The impact of somnolence on continuing guanfacine treatment is unclear. Therefore, we investigated the reasons for discontinuing guanfacine and analyzed the factors associated with discontinuation caused by somnolence. We surveyed 96 patients under guanfacine from July 2017 to December 2021 at the Saga University Hospital. Patients who discontinued guanfacine by the end date of our study were divided into a median early and late group. We compared the reasons for discontinuation in both groups. Of all patients, 47 continued and 49 discontinued guanfacine. A higher percentage of patients discontinued guanfacine caused by somnolence for ≤70 d than for >70 d of treatment (44.0 vs. 8.3%; p = 0.008). When stratified by the concomitant use of other ADHD drugs, somnolence resulted in a higher discontinuation rate for ≤70 d than for >70 d of treatment without concomitant use (55.0 vs. 7.1%; p = 0.009). Nonetheless, concomitant use resulted in no difference. In conclusion, somnolence affects the early discontinuation of guanfacine as an ADHD drug. The combination of methylphenidate or atomoxetine may decrease withdrawal caused by somnolence.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GuanfacineAttention Deficit Disorder with HyperactivityHumansMaleFemaleChildAdolescentSleepinessAdrenergic alpha-2 Receptor AgonistsMethylphenidate

Stichwörter der Autor:innen

adverse eventattention-deficit/hyperactivity disordercombination therapyguanfacinesomnolence

Substanzen

GuanfacineAdrenergic alpha-2 Receptor AgonistsMethylphenidate

Autor:innen und Institutionen

  • Department of Pharmacy, Saga University Hospital.
  • Eguchi Hospital.
  • Department of Pediatrics, Faculty of Medicine, Saga University.

Zitieren

APA

Doi, K., Sogawa, R., Eguchi, Y., Matsuo, M., & Shimanoe, C. (2024). Association between Early Guanfacine Discontinuation and Somnolence for Attention-Deficit/Hyperactivity Disorder. Biological and Pharmaceutical Bulletin. https://doi.org/10.1248/bpb.b24-00147

Vancouver

Doi K, Sogawa R, Eguchi Y, Matsuo M, Shimanoe C. Association between Early Guanfacine Discontinuation and Somnolence for Attention-Deficit/Hyperactivity Disorder. Biological and Pharmaceutical Bulletin. 2024. doi:10.1248/bpb.b24-00147

BibTeX
@article{Doi2024,
  author = {Doi, Kinuka and Sogawa, Rintaro and Eguchi, Yuko and Matsuo, Muneaki and Shimanoe, Chisato},
  title = {Association between Early Guanfacine Discontinuation and Somnolence for Attention-Deficit/Hyperactivity Disorder},
  journal = {Biological and Pharmaceutical Bulletin},
  year = {2024},
  doi = {10.1248/bpb.b24-00147}
}
Kostenlos starten →